Clinical Trials
22 trialsNCT03937830 2026-05-22
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT07391670 2026-05-15
IMFINZI-subQ
AstraZeneca
Phase 1 Recruiting
NCT07012798 2026-05-13
FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07081633 2026-05-12
TREMENDOUS-2
AstraZeneca
Phase 2 Active not recruiting
NCT05027425 2026-05-06
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
University of Cincinnati
Phase 2 Terminated
NCT07122089 2026-05-05
IOSPHERE
Center Eugene Marquis
Phase 2 Recruiting
NCT07226063 2026-05-05
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03482102 2026-05-04
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07166406 2026-05-04
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT06710223 2026-04-30
Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab
University of California, San Diego
Phase 1 Recruiting
NCT05063565 2026-04-29
ROWAN
Boston Scientific Corporation
Phase 2 Active not recruiting
NCT06045975 2026-04-24
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Active not recruiting
NCT03942328 2026-04-20
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT04605731 2026-04-20
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
City of Hope Medical Center
Phase 1 Active not recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Phase 2 Recruiting
NCT03298451 2026-03-20
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT06040099 2026-03-19
EMERALD-Y90
AstraZeneca
Phase 2 Active not recruiting
NCT03847428 2026-03-06
EMERALD-2
AstraZeneca
Phase 3 Active not recruiting